Myriad Genetics (NASDAQ:MYGN) Upgraded to Neutral at Piper Sandler

Posted by Francis Steltz on Oct 20th, 2026

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by research analysts at Piper Sandler from an “underweight” rating to a “neutral” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $5.00 target price on the stock. Piper Sandler’s price objective indicates a potential downside of 13.13% from the company’s current price.

MYGN has been the subject of several other research reports. Craig Hallum lifted their price objective on Myriad Genetics from $4.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Wall Street Zen cut shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. TD Cowen upped their price objective on Myriad Genetics from $4.00 to $4.50 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 15th. Finally, Stephens cut their price objective on shares of Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Myriad Genetics presently has an average rating of “Hold” and an average target price of $4.52.

Read Our Latest Stock Report on MYGN

Myriad Genetics Stock Performance

Myriad Genetics stock traded up $1.55 during mid-day trading on Tuesday, reaching $5.76. The company’s stock had a trading volume of 19,372,363 shares, compared to its average volume of 1,839,529. Myriad Genetics has a 12-month low of $2.74 and a 12-month high of $8.50. The company has a market capitalization of $550.56 million, a P/E ratio of -4.84 and a beta of 1.64. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. The firm’s fifty day moving average price is $3.68 and its two-hundred day moving average price is $4.36.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.19). The company had revenue of $190.70 million during the quarter, compared to the consensus estimate of $206.03 million. Myriad Genetics had a negative return on equity of 16.09% and a negative net margin of 13.96%. Myriad Genetics’s revenue was down 10.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 earnings per share. Sell-side analysts predict that Myriad Genetics will post -0.99 EPS for the current fiscal year.

Institutional Trading of Myriad Genetics

Large investors have recently added to or reduced their stakes in the stock. Allworth Financial LP purchased a new position in shares of Myriad Genetics during the second quarter valued at about $25,000. Integrated Wealth Concepts LLC purchased a new position in shares of Myriad Genetics in the 2nd quarter valued at approximately $54,000. Hsbc Holdings PLC purchased a new position in Myriad Genetics during the second quarter valued at $61,000. E Fund Management Co. Ltd. purchased a new stake in shares of Myriad Genetics in the 2nd quarter worth about $67,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Myriad Genetics in the 2nd quarter worth about $69,000. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Company Profile

(Get Free Report)

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests designed to help healthcare professionals assess disease risk, guide treatment decisions and support patient care. The company serves physicians, hospitals, health systems, biopharmaceutical companies and patients, with a focus on areas including oncology, women’s health and mental health.

Its portfolio includes hereditary cancer testing, such as the MyRisk Hereditary Cancer test; tumor profiling and companion diagnostic services used to help inform cancer treatment; prenatal and carrier screening tests, including Prequel and Foresight; and pharmacogenomic testing, including GeneSight, which is intended to help clinicians evaluate how a patient may respond to certain psychiatric medications.